Latest news with #Recbio
India Gazette
01-07-2025
- Health
- India Gazette
BE to manufacture HPV9 vaccine for India, UNICEF and PAHO tender markets
Hyderabad (Telangana) [India], July 1 (ANI): Jiangsu Recbio Technology Company Limited ( announced that they have entered into a licensing cooperation agreement, and have commenced the technology transfer of their Recombinant 9-valent HPV (HPV9) vaccine, REC603, to Biological E. Limited (BE), a leading Indian vaccine and pharmaceutical company. Recbio will provide BE with Drug Substance (DS) and transfer technology to formulate, fill, and package vaccines. It will also include technology transfer for DS production at an appropriate time in the future. According to the agreement, BE will receive the exclusive right to commercialise the vaccine in India and participate in UNICEF & PAHO tenders in other markets. The HPV9 vaccine is a recombinant vaccine designed to protect against nine types of Human Papillomavirus (HPV), including those responsible for cervical, vulvar, vaginal, anal, and oropharyngeal cancers, as well as genital warts. HPV is a group of over 200 known viruses, some of which are classified as high-risk due to their potential to cause cancer. While most HPV infections are controlled by the body's immune system, persistent infections with high-risk HPV types can lead to cervical cancer and other malignancies affecting the vulva, vagina, mouth, throat, penis, and anus. In 2019 alone, HPV was linked to an estimated 620,000 cancer cases in women and 70,000 in men. Preventive vaccination, alongside HPV screening and treatment of pre-cancerous lesions, is a key strategy in reducing the global burden of HPV-related cancers. Cervical cancer is the fourth leading cause of cancer-related deaths among women worldwide. The 9-valent HPV vaccine is effective in preventing around 90 percent of cervical cancer and 90 percent of anal and genital warts. Recbio's core product, REC603, is for people ranging from 9 to 45 years old and is currently in the crucial Phase III clinical trials in China. Following the signing of the technology license agreement, Recbio has begun transferring the necessary technical knowledge, materials, and expertise to BE to produce the HPV9 vaccine. Recbio will continue to support BE in clinical development and regulatory approvals to ensure a seamless transition. This collaboration comes at a crucial time, as the global demand for cervical cancer prevention is at an all-time high. By leveraging BE's advanced manufacturing capabilities, this partnership aims to increase the availability of an affordable HPV9 vaccine in India and across international markets. BE will begin large-scale manufacturing of the HPV9 vaccine once the Technology transfer is completed. This collaboration marks a significant milestone for Recbio in entering the Indian and international markets, highlighting its potential in the innovative vaccine field. Dr. Liu Yong, Founder, Chairman, and CEO of Recbio, stated, 'We are delighted to collaborate with Biological E. Limited. This cooperation is another significant progress for Recbio in expanding into international markets., We will work together with our Indian partner to accelerate the launch process of the HPV9 vaccine in India, and jointly make greater contributions to global public health.' Mahima Datla, Managing Director, Biological E. Limited, said: 'We are pleased to partner with Recbio to bring the HPV9 vaccine to India and other countries. This collaboration aligns with our commitment to improving global health by making essential vaccines more accessible and affordable as well as to promote a lasting legacy of innovation and stewardship. We, along with Recbio, are committed to creating a healthier and more robust future by ensuring that this life-saving vaccine is delivered to those who need it the most.' (ANI)
New Indian Express
01-07-2025
- Health
- New Indian Express
Recbio, Biological E ink deal for HPV9 vaccine
HYDERABAD: Jiangsu Recbio Technology Co. Ltd, a leading Chinese biopharmaceutical firm, has entered into a licensing and technology transfer agreement with Hyderabad-based Biological E Limited (BE) for its Recombinant 9-valent HPV (HPV9) vaccine, REC603. The HPV9 vaccine is designed to protect against nine strains of Human Papillomavirus, including those linked to cervical, vulvar, vaginal, anal, oropharyngeal cancers and genital warts. Under the agreement, BE will receive exclusive rights to commercialise the vaccine in India and participate in global tenders by UNICEF and PAHO. According to a release, Recbio will supply the Drug Substance (DS) and transfer formulation, filling and packaging technologies to BE. DS production technology will also be transferred at a later stage. Recbio has started sharing the necessary technical expertise, materials and knowledge with BE to begin local production. It will also support BE through clinical development and regulatory approvals. The partnership aims to meet the growing global demand for cervical cancer prevention, the release said, adding that large-scale manufacturing will begin after the technology transfer is complete. Dr Liu Yong, Recbio's chairman and CEO, called the deal a major step in global expansion. Mahima Datla, MD of BE, said the partnership reflects their commitment to making life-saving vaccines more accessible and affordable.
Time of India
01-07-2025
- Health
- Time of India
Biological E to manufacture HPV9 vaccine for India, UNICEF and PAHO tender markets
Synopsis Jiangsu Recbio Technology and Biological E. Limited are partnering for HPV9 vaccine. Recbio will transfer technology to Biological E. Limited. This will allow Biological E. Limited to manufacture and commercialize the vaccine. The goal is to make the vaccine accessible in India and other markets. This collaboration aims to prevent cervical cancer.
The Hindu
30-06-2025
- Business
- The Hindu
Biological E. to produce Jiangsu Recbio Tech's HPV9 vaccine REC603
Hyderabad-based vaccine maker Biological E. will produce Chinese biopharmaceutical firm Jiangsu Recbio Technology Company's recombinant 9-valent HPV (HPV9) vaccine REC603 under a licensing cooperation agreement the companies announced on Monday. The Hong Kong stock exchange listed Recbio, under the agreement, will provide BE with drug substance (DS) and transfer technology to formulate, fill and package the vaccines. Technology transfer for the DS production will be given at an appropriate time in future, the companies said in a release. BE will receive exclusive right to commercialise the vaccine in India and participate in UNICEF and PAHO tenders in other markets. It will begin large-scale manufacturing of the HPV9 vaccine once the technology transfer is completed. The HPV9 vaccine is a recombinant vaccine designed to protect against nine types of Human Papillomavirus (HPV), including those responsible for cervical, vulvar, vaginal, anal and oropharyngeal cancers as well as genital warts. Following the license agreement, Recbio has started transferring necessary technical knowledge, materials and expertise to BE for producing the vaccine. It will continue to support BE in clinical development and regulatory approvals. Their collaboration comes at a time when the global demand for cervical cancer prevention is at an all-time high. By leveraging BE's advanced manufacturing capabilities, their partnership aims to increase the availability of an affordable HPV9 vaccine in India and across international markets, the companies said. 'This cooperation is another significant progress for Recbio in expanding into international markets., We will work together with our Indian partner to accelerate the launch process of the HPV9 vaccine in India and jointly make greater contributions to global public health,' Founder, Chairman and CEO of Recbio Liu Yong said. The Chinese firm has a portfolio of at least 10 high-value innovative vaccines covering major disease areas such as cervical cancer, herpes zoster and respiratory syncytial virus. REC603, one of its core products, is for people aged 9-45 years and currently in the phase III clinical trials in China. BE Managing Director Mahima Datla the company and Recbio are committed to ensure the life-saving vaccine is delivered to those who need it the most.
&w=3840&q=100)
Business Standard
30-06-2025
- Health
- Business Standard
Biological E to make HPV9 vaccine under licensing pact with Recbio
Hyderabad-based vaccine manufacturer Biological E (BE) on Monday announced it has entered a licensing agreement with Chinese pharma firm Jiangsu Recbio Technology Company to produce and commercialise Recbio's nine-valent Human Papillomavirus (HPV9) vaccine for India and global markets. The HPV9 vaccine, designed to protect against nine HPV types linked to cervical, vulvar, vaginal, anal and oropharyngeal cancers, as well as genital warts, is currently in Phase 3 clinical trials in China. As part of the agreement, BE will receive the exclusive right to commercialise the vaccine in India and participate in UNICEF and PAHO tenders in other markets. Recbio will also provide BE with the drug substance (DS) and transfer the technology to formulate, fill, and package the vaccines. 'It will also include technology transfer for DS production at an appropriate time in the future,' Recbio said in a statement. In India, the estimated number of deaths due to cervical cancer stood at 35,691 in 2023, up from 34,806 in 2022 and 33,938 in 2021, according to a parliamentary response by the Union Health Ministry. Recbio claims that the nine-valent HPV vaccine is effective in preventing around 90 per cent of cervical cancers and 90 per cent of anal and genital warts. Commenting on the collaboration, Mahima Datla, Managing Director at BE, said the partnership aligns with the company's commitment to improve global health by making essential vaccines more accessible and affordable. The collaboration also marks a significant milestone for Recbio in entering the Indian and international markets, highlighting its potential in the innovative vaccine field. Liu Yong, Founder, Chairman and Chief Executive Officer (CEO) of Recbio, added that it will work together with BE to accelerate the launch process of the HPV9 vaccine in India. Following the signing of the technology licence agreement between the two companies, Recbio has begun transferring the necessary technical knowledge, materials, and expertise to BE to produce the HPV9 vaccine. BE is expected to begin large-scale manufacturing of the HPV9 vaccine once the technology transfer is completed. Currently, BE supplies its vaccines to more than 140 countries, and its therapeutic products are sold in India, the US and Europe. It had recently received approval for India's first 14-valent Pneumococcal Conjugate Vaccine.
